Cryoport 경영진
경영진 기준 점검 3/4
Cryoport CEO는 Jerry Shelton, Nov2012 에 임명되었습니다 의 임기는 13.5 년입니다. 총 연간 보상은 $2.38M, 40.7% 급여 및 59.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $17.31M 가치에 해당하는 회사 주식의 2.44% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 6.3 년과 11.9 년입니다.
핵심 정보
Jerry Shelton
최고경영자
US$2.4m
총 보수
| CEO 급여 비율 | 40.74% |
| CEO 재임 기간 | 13.5yrs |
| CEO 지분 보유율 | 2.4% |
| 경영진 평균 재임 기간 | 6.3yrs |
| 이사회 평균 재임 기간 | 11.9yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.
내러티브 업데이트 • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.내러티브 업데이트 • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.내러티브 업데이트 • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.내러티브 업데이트 • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).내러티브 업데이트 • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).내러티브 업데이트 • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).내러티브 업데이트 • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.내러티브 업데이트 • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.내러티브 업데이트 • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.내러티브 업데이트 • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.내러티브 업데이트 • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.내러티브 업데이트 • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.내러티브 업데이트 • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.분석 기사 • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...분석 기사 • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...분석 기사 • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
새로운 내러티브 • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.분석 기사 • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...분석 기사 • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...분석 기사 • Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...분석 기사 • Jul 22
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Jun 25
Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Cryoport, Inc. ( NASDAQ:CYRX ) share price has dived 28% in the last thirty...분석 기사 • Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
It's not a stretch to say that Cryoport, Inc.'s ( NASDAQ:CYRX ) price-to-sales (or "P/S") ratio of 3.7x right now seems...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$45m |
| Dec 31 2025 | US$2m | US$968k | -US$42m |
| Sep 30 2025 | n/a | n/a | -US$48m |
| Jun 30 2025 | n/a | n/a | -US$38m |
| Mar 31 2025 | n/a | n/a | -US$104m |
| Dec 31 2024 | US$2m | US$921k | -US$113m |
| Sep 30 2024 | n/a | n/a | -US$158m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$117m |
| Dec 31 2023 | US$2m | US$866k | -US$93m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$2m | US$792k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$296m |
| Jun 30 2022 | n/a | n/a | -US$297m |
| Mar 31 2022 | n/a | n/a | -US$293m |
| Dec 31 2021 | US$5m | US$713k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$78m |
| Mar 31 2021 | n/a | n/a | -US$77m |
| Dec 31 2020 | US$5m | US$613k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$22m |
| Jun 30 2020 | n/a | n/a | -US$23m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$4m | US$600k | -US$18m |
보상 대 시장: Jerry의 총 보수(USD2.38M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.79M)보다 낮습니다.
보상과 수익: Jerry의 보상은 회사가 적자임에도 증가했습니다.
CEO
Jerry Shelton (80 yo)
13.5yrs
재임 기간
US$2,375,524
보수
Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman | 13.5yrs | US$2.38m | 2.44% $ 17.3m | |
| Senior VP | 14.9yrs | US$1.12m | 0.55% $ 3.9m | |
| Senior VP and Chief Digital & Technology Officer | 2.3yrs | US$1.09m | 0.22% $ 1.5m | |
| Senior VP & Chief Scientific Officer | 5.7yrs | US$986.06k | 0.20% $ 1.4m | |
| Vice President of Corporate Development & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| VP, General Counsel & Corporate Secretary | no data | 데이터 없음 | 데이터 없음 | |
| Vice President of Global Human Resources & Organizational Development | no data | 데이터 없음 | 데이터 없음 | |
| Chief Operating Officer of Cryoport Systems | 6.3yrs | 데이터 없음 | 데이터 없음 |
6.3yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 관리: CYRX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman | 13.6yrs | US$2.38m | 2.44% $ 17.3m | |
| Senior VP and Chief Digital & Technology Officer | 12.7yrs | US$1.09m | 0.22% $ 1.5m | |
| Independent Director | 5.2yrs | US$421.79k | 0.11% $ 812.6k | |
| Member of Commercial Advisory Board | 13.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 10.7yrs | US$419.07k | 0.10% $ 721.4k | |
| Independent Director | 5.6yrs | US$70.00k | 데이터 없음 | |
| Member of Advisory Board | 18.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 11.9yrs | US$430.97k | 0.11% $ 809.6k | |
| Independent Director | 7.3yrs | US$395.07k | 0.12% $ 826.0k |
11.9yrs
평균 재임 기간
66.5yo
평균 나이
경험이 풍부한 이사회: CYRX의 이사회는 노련하고 경험이 풍부합니다(평균 재임 11.9 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 12:57 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cryoport, Inc.는 14명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |